Oncolys BioPharma (TSE:4588) Short-Term Debt: 円687.22 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
40 GF Score
Price 円3,250.00
GF Value 円356.20
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Oncolys BioPharma Short-Term Debt?

Oncolys BioPharma TSE:4588 -3.56% 40 Short-Term Debt is 円687.22 Mil as of Jun. 2026. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円356.20 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Oncolys BioPharma's Short-Term Debt for the quarter that ended in Jun. 2026 was 円687.22 Mil.

Oncolys BioPharma's quarterly Short-Term Debt increased from Dec. 2025 (円233.33 Mil) to Mar. 2026 (円662.22 Mil) and increased from Mar. 2026 (円662.22 Mil) to Jun. 2026 (円687.22 Mil).

Oncolys BioPharma's annual Short-Term Debt stayed the same from Dec. 2023 (円127.78 Mil) to Dec. 2024 (円127.78 Mil) but then increased from Dec. 2024 (円127.78 Mil) to Dec. 2025 (円233.33 Mil).

Oncolys BioPharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Oncolys BioPharma Short-Term Debt Related Terms

Oncolys BioPharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Oncolys BioPharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma Short-Term Debt Chart

Oncolys BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 238.88 227.78 127.78 127.78 233.33

Oncolys BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.67 147.22 233.33 662.22 687.22
TSE:4588
40GF Score
Oncolys BioPharma Inc TSE:4588
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of 円687.22 Mil mean?
Oncolys BioPharma (TSE:4588) has a Short-Term Debt of 円687.22 Mil as of Jun. 2026.
Is Oncolys BioPharma's Short-Term Debt too high?
Oncolys BioPharma's current Short-Term Debt is 円687.22 Mil. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Short-Term Debt compare to VRTX and REGN?
Oncolys BioPharma's Short-Term Debt of 円687.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Oncolys BioPharma's current Short-Term Debt is 円687.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円356.20, compared to a current price of 円3,250.00 — trading 812.4% above its estimated fair value. The current Short-Term Debt is 円687.22 Mil. Oncolys BioPharma's overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Short-Term Debt is 円687.22 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円3,250.00 is trading 812.4% above its estimated GF Value™ of 円356.20. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • Short-Term Debt: 円687.22 Mil
  • GF Value™: 円356.20 vs. price of 円3,250.00 (812.4% above fair value)
  • GF Score™: 40/100 with 8 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score

Get the complete analysis for TSE:4588

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,250.00
Price
円356.20
GF Value